학술논문

Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review
Document Type
article
Source
Human Vaccines & Immunotherapeutics, Vol 18, Iss 5 (2022)
Subject
vaccine
covid-19
waning
older adults
effectiveness
Immunologic diseases. Allergy
RC581-607
Therapeutics. Pharmacology
RM1-950
Language
English
ISSN
2164-5515
2164-554X
21645515
Abstract
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July–October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.